根据最近的SEC文件，专注于纤维化疾病和癌症治疗开发的制药公司Galectin Therapeutics Inc. (NASDAQ: GALT )于2025年1月23日结束了2024年度股东大会，市值为7657万美元。股东就几个关键事项进行了投票。

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Galectin Therapeutics (GALT) 64.20% +3.11, ...

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line ...

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug ...

Geneos Wealth Management Inc. raised its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 10.2% in the 4th ...

H.C. Wainwright analyst Ed Arce downgraded Galectin Therapeutics (GALT) to Neutral from Buy with no price target after the company’s Phase 2b ...